CO6351797A2 - Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso - Google Patents

Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso

Info

Publication number
CO6351797A2
CO6351797A2 CO11014849A CO11014849A CO6351797A2 CO 6351797 A2 CO6351797 A2 CO 6351797A2 CO 11014849 A CO11014849 A CO 11014849A CO 11014849 A CO11014849 A CO 11014849A CO 6351797 A2 CO6351797 A2 CO 6351797A2
Authority
CO
Colombia
Prior art keywords
methods
triol
phenyl
tetrahydro
solid forms
Prior art date
Application number
CO11014849A
Other languages
English (en)
Inventor
Paul Susan Margaret De
Anett Perlberg
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CO6351797A2 publication Critical patent/CO6351797A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se dirige, en parte, a formas sólidas amorfas y cristalinas de (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibencil) fenil)-6-(metiltio) tetrahidro-2H- piran-3,4,5-triol anhidro, que es un inhibidor del co-transportador de glucosa sodio tipo 2, y puede ser útil en el tratamiento de diabetes y una variedad de otras enfermedades y afecciones. Esta invención también se dirige a formas de dosificación que comprenden formas sólidas de (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibencil)fenil)-6- (metiltio) tetrahidro-2H-piran-3,4,5-triol anhidro, y con métodos para su uso.Una modalidad de la invención abarca las composiciones farmacéuticas que comprenden las formas sólidas descritas aquí.Otra modalidad abarca métodos para inhibir la actividad SGLT2, así como también métodos para tratar, prevenir y manejar una variedad de enfermedades y trastornos, utilizando las formas sólidas descritas aquí.
CO11014849A 2008-07-17 2011-02-09 Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso CO6351797A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17

Publications (1)

Publication Number Publication Date
CO6351797A2 true CO6351797A2 (es) 2011-12-20

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11014849A CO6351797A2 (es) 2008-07-17 2011-02-09 Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso

Country Status (29)

Country Link
US (2) US8217156B2 (es)
EP (1) EP2332947B1 (es)
JP (2) JP2011528366A (es)
KR (2) KR101707246B1 (es)
CN (2) CN107629097A (es)
AR (1) AR072807A1 (es)
AU (1) AU2009270973B2 (es)
BR (1) BRPI0916191A2 (es)
CA (1) CA2730931A1 (es)
CL (1) CL2009001595A1 (es)
CO (1) CO6351797A2 (es)
DK (1) DK2332947T3 (es)
ES (1) ES2656357T3 (es)
HK (1) HK1243713A1 (es)
HU (1) HUE035400T2 (es)
IL (1) IL210269A (es)
MX (1) MX2011000503A (es)
NO (1) NO2332947T3 (es)
NZ (1) NZ590184A (es)
PE (1) PE20100260A1 (es)
PL (1) PL2332947T3 (es)
PT (1) PT2332947T (es)
RU (1) RU2505543C2 (es)
SG (1) SG185317A1 (es)
TW (1) TWI472521B (es)
UA (1) UA106048C2 (es)
UY (1) UY31992A (es)
WO (1) WO2010009197A1 (es)
ZA (1) ZA201100175B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN101801989B (zh) 2007-07-26 2015-11-25 莱西肯医药有限公司 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
EP2312944B1 (en) 2008-07-15 2018-09-05 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9200025B2 (en) * 2012-11-20 2015-12-01 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
MX2018001022A (es) 2015-07-30 2018-05-17 Microbial Chem Res Found Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.
JP6727419B2 (ja) * 2016-05-25 2020-07-22 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
CN109843279A (zh) 2016-10-19 2019-06-04 勃林格殷格翰国际有限公司 包含ssao/vap-1抑制剂和sglt2抑制剂的药物组合、其用途
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
WO2020068661A1 (en) * 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
EP3957634A4 (en) * 2019-07-05 2022-08-31 Shangdong Danhong Pharmaceutical Co., Ltd. CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION
EP3771718A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
US20240100013A1 (en) 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
WO2022155303A1 (en) 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2595257A1 (en) 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN101801989B (zh) * 2007-07-26 2015-11-25 莱西肯医药有限公司 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
HUE035400T2 (en) 2018-05-02
RU2011105797A (ru) 2012-08-27
CL2009001595A1 (es) 2010-07-19
AR072807A1 (es) 2010-09-22
EP2332947B1 (en) 2017-11-01
TWI472521B (zh) 2015-02-11
KR20170010069A (ko) 2017-01-25
HK1243713A1 (zh) 2018-07-20
CN102112483A (zh) 2011-06-29
IL210269A0 (en) 2011-03-31
NO2332947T3 (es) 2018-03-31
JP2016041701A (ja) 2016-03-31
US8217156B2 (en) 2012-07-10
UY31992A (es) 2010-02-26
PL2332947T3 (pl) 2018-04-30
PT2332947T (pt) 2018-02-06
JP6283337B2 (ja) 2018-02-21
SG185317A1 (en) 2012-11-29
CN107629097A (zh) 2018-01-26
MX2011000503A (es) 2011-03-01
WO2010009197A1 (en) 2010-01-21
BRPI0916191A2 (pt) 2017-08-29
IL210269A (en) 2015-06-30
EP2332947A1 (en) 2011-06-15
RU2505543C2 (ru) 2014-01-27
ZA201100175B (en) 2012-03-28
DK2332947T3 (da) 2018-01-29
TW201006808A (en) 2010-02-16
UA106048C2 (uk) 2014-07-25
US9067962B2 (en) 2015-06-30
PE20100260A1 (es) 2010-04-16
US20100016422A1 (en) 2010-01-21
AU2009270973B2 (en) 2014-01-30
US20130165395A1 (en) 2013-06-27
AU2009270973A1 (en) 2010-01-21
ES2656357T3 (es) 2018-02-26
KR101707246B1 (ko) 2017-02-15
CA2730931A1 (en) 2010-01-21
JP2011528366A (ja) 2011-11-17
KR20110031196A (ko) 2011-03-24
NZ590184A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
CO6351797A2 (es) Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso
AR084781A1 (es) Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
EA201391651A1 (ru) Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
NZ595382A (en) Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea
NO20075111L (no) Farmasoytisk sammensetning
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
BRPI0609424B8 (pt) composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA108887C2 (xx) Кристалічна форма бензил-бензольного інгібітора sglt2
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR9782A (es) Composiciones de carbohidratos obtenidas a partir de hongos basidiomicetes para ser utilizadas como agentes biocidas contra patogenos
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
AR118208A1 (es) Composiciones para evitar, mejorar o tratar enfermedades o síntomas relacionados con los cartílagos, que comprenden hapln1
AR055658A1 (es) Composiciones fungicidas
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos
WO2012173410A3 (en) Novel c-aryl ansa sglt2 inhibitors
TH122363A (th) รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้
TH122363B (th) รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้
CU20110041A7 (es) Derivados de dioxa-biciclo(3.2.1)octano-2,3,4-triol
NZ604558A (en) Deuterated benzylbenzene derivatives and methods of use

Legal Events

Date Code Title Description
FC Application refused